Royal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $19.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target upped by analysts at Royal Bank Of Canada from $18.00 to $19.00 in a research note issued to investors on Tuesday,MarketScreener reports. The firm currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target would indicate a potential downside of 17.68% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. Wedbush raised their price target on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 26th. Oppenheimer reissued an “outperform” rating and issued a $37.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Wells Fargo & Company cut their target price on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Jefferies Financial Group reiterated a “buy” rating and set a $30.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Finally, Barclays assumed coverage on Sarepta Therapeutics in a report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $32.63.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $23.08 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $64.80. The stock has a market capitalization of $2.42 billion, a P/E ratio of -2.73, a price-to-earnings-growth ratio of 0.36 and a beta of 0.29. The stock has a fifty day moving average of $18.79 and a 200-day moving average of $20.26.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. During the same period last year, the business earned $1.90 earnings per share. The business’s quarterly revenue was down 32.7% compared to the same quarter last year. On average, sell-side analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at approximately $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth approximately $25,000. iSAM Funds UK Ltd bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth about $25,000. Ancora Advisors LLC grew its stake in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares during the period. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $33,000. Finally, Allworth Financial LP raised its stake in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.